PROFESSIONAL EXPERIENCES

Current Employment:
2019-present Senior Conway Fellow, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD), Dublin, Ireland
2018-present Guest Professor, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, China
2018-present Adjunct Professor, School of Mechanical and Materials Engineering, University College Dublin (UCD), Dublin, Ireland
2018-present Professor, Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), Dublin, Ireland
2018-present Founder & Chairman & CSO, Blafar Ltd.
2019-present Founder & Chairman, Branca Bunús Ltd.
2011-present Science Foundation Ireland (SFI) Principal Investigator, Ph.D., FRSC (Fellow of The Royal Society of Chemistry)

Previous Employment:
2013-2018 Associate Professor, Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), Dublin, Ireland
2010-2018 Founder & Chairman & CSO, Vornia Ltd. (acquired by Ashland Inc.)
11.2013 Professor in Synthetic/Polymer Chemistry, the Faculty of Science and Engineering, University of Wolverhampton, UK
2009-2013 Science Foundation Ireland (SFI) Stokes Lecturer in Functional Biomaterials, Network of Excellence for Functional Biomaterials (NFB), National Centre for Biomedical Engineering Science (NCBES), Department of Mechanical and Biomedical Engineering, College of Engineering & Informatics, National University of Ireland, Galway, (NUI Galway), Ireland
2008-2009 University Fellow (Teaching and Research) in Biomedical Engineering (Functional Biomaterials), NUI Galway, Ireland
2007-2008 Senior Research Fellow, Advanced Drug Delivery and Tissue Engineering Group, School of Pharmacy, the University of Nottingham, UK
2001-2006 Senior Research Fellow, Green Chemistry Group, School of Chemistry, the University of Nottingham, UK
2000-2001 Research Fellow, Centre for Education and Research on Macromolecules (CERM), University of Liege, Belgium

Biography:
Wenxin Wang is Full Professor in Skin Research and Wound Healing, a Science Foundation Ireland (SFI) Principal Investigator at the Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), and a member of UCD Academic Council. He won the highly prestigious “Young Scientist Prize in Regenerative Medicine” in 2010 at TERMIS-EU conference, the “SFI Principal Investigator award” in 2011 and the DEBRA Award for Excellent EB Patient Service in 2014, which highlight his work ethic and achievements. Prof. Wang’s scientific interests are in the areas of biomaterials, stem cell and gene therapy for the treatments of skin wounds, cartilage/bone regeneration, dental tissue regeneration, tissue sealant/adhesive. His scientific contribution and achievements have been recognized both nationally and internationally including 251 peer-reviewed scientific journal papers (Nat. Commun., Nat. Rev. Chem., Sci. Adv., Angew. Chem., JACS, Chem. Sci., ACS Nano and Nano Letters etc.), 5 book chapters, 36 patents, 174 conference abstracts and presentations, and 123 invited lectures and keynote presentations. Since 2009 he has graduated 27 PhD students and mentored over 29 postdoctoral researchers. His achievements have gained the increased interest in the wider public community with publicity media activities (56 times in TV Documentary, Videos and Newspapers), for example in RTE-TV, ‘The Sunday Times’, ‘The Irish Times’, ‘Science Daily’ and ‘Chemistry World’. He has been awarded significant funding (ca. 13.62 million Euros) from different sources, e.g., SFI, Health Research Board (HRB), Irish Research Council (IRC), Enterprise Ireland (EI) and European Union (EU-FP7 & EU Horizon 2020) to support his research activities. Prof. Wang has acted as the symposium convener and chair, the member of organizing committees and the member of the conference advisory board for 34 international conferences and has been selected as an expert reviewer and panel member by 28 international research councils and funding bodies. As the founder, Prof Wang has launched 3 companies - Vornia Ltd (www.vornia.com, acquired by Ashland - a Fortune500 US company in Jan. 2018, renamed as Ashland Specialties Ireland), Blafar Ltd. (www.blafar.com), and Branca Bunús Ltd. (www.brancabunus.com). These three companies currently hire 25 employees in Ireland. Furthermore, he has 30 patents in collaboration with industry partners: Ashland, Amryt Biopharm, Blafar and Branca Bunús, and successfully launched and commercialized 5 newly developed technologies onto the market.

COMMERCIALIZATION

•Founder & Chairman & CSO: Vornia Ltd. (acquired by Ashland Inc.), website: www.vornia.com
•Founder & Chairman & CSO: Blafar Ltd., website: www.blafar.com
•Founder & Chairman: Branca Bunús Ltd., website: www.brancabunus.com
•Intellectual Properties: 36 Granted Patents; 20 Filled Patent Applications; 30 Licensed IPs to industry partners: Ashland Specialties Ireland Ltd., Blafar Ltd., Branca Bunús Ltd. and Amryt Biopharma.
•Successfully launched and commercialized 5 newly developed technologies onto the market.

PROFESSIONAL SOCIETY MEMBERSHIPS

•Fellow of Royal Society of Chemistry (FRSC)
•Member of Tissue Engineering and Regenerative Medicine International Society (TERMIS)
•Member of European Society for Biomaterials (ESB)

E-mail: [email protected]
Prof. Wenxin Wang University Webpage: https://people.ucd.ie/wenxin.wang

Research Project
•Epidermolysis Bullosa
•Gene therapy
•Animal experimentation

Email: [email protected]

Research Project
•Monte Carlo simulation
•Controlled/living polymerization

Email: [email protected]

Research Project
•Gene therapy for EB
•Gene transfection

Email: [email protected]

Research Project
•Formulation and characterisation of HA-based hydrogel
•Exosomes loaded Injectable hydrogel for chronic wound healing

Email: [email protected]

Research Project
•Functionalisation of ECM-based biopolymers
•Wound healing

Email: [email protected]

Research Project
•Highly branched poly(β-amino ester)s
•Gene delivery

Email: [email protected]

Research Project
• Polymer-based non-viral gene delivery
• Epidermolysis Bullosa (EB) gene therapy

Email: [email protected]

DTIF Project
•A Disruptive Gene Therapy Platform
•Replacing Viruses in the Treatment of Genetic Conditions

Email: [email protected]

Research Project
•Functionalisation of ECM-based biopolymers

Email: [email protected]

Research Project
•Controlled/living radical polymerization (ATRP, Cu(0)-mediated RDRP and RAFT)
•Controlled polymerization of multivinyl monomers towards various applications

Email: [email protected]

Research Project
• Epidermolysis Bullosa
• Gene Therapy
• Plasmids

Email: [email protected]

Research Project
• Injectable hydrogel
• Drug delivery

Email: [email protected]

Research Project
• Advanced Drug Delivery Systems
• Multifunctional Applications of Peptides in Biomedicine

Email: [email protected]

Research Project
• Single chain cyclized polymers
• Tough biocompatible hydrogels

Email: [email protected]

Research Project
• Injectable hydrogel for wound healing
• Gene therapy

Email: [email protected]

Research Project
• Polymer-based non-viral gene deliver
• Epidermolysis Bullosa (EB) gene therapy

Email: [email protected]

Research Project
• Biopolymer hydrogel regulating stem cell fate

Email: [email protected]

Research Project
• Functional drug delivery system
• Exosome loaded hydrogel

Email: [email protected]

Research Project
• Polymerization mechanism
• Monte Carlo kinetics simulation

Email: [email protected]

Research Project
•Controlled/living polymerization
•Computational chemistry

Email: [email protected]

Research Project
•In situ formed hydrogel scaffold combining stem cell for the wound healing

Email: [email protected]

Research Project
•Gene therapy
•Intracellular interactions of gene delivery materials

Email: [email protected]

Research Project
•chronic wound
•Stem cell treatment and Cell engineering

Email: [email protected]

Research Project
•RAFT polymerization
•Polysaccharide
•Gene delivery

Email: [email protected]